Inhibition of parathyroid hormone: A dose equivalency study of paricalcitol and doxercalciferol

American Journal of Nephrology

Volumn 25, Issue 6, 2005, Pages 591-595

  Zisman, Anna L ^a   Ghantous, Walid ^a   Schinleber, Pamela ^a   Roberts, Laurie ^a   Sprague, Stuart M ^a,b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dose equivalency; Doxercalciferol; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

ALBUMIN; CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LINEAR REGRESSION ANALYSIS; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED;

EID: 29144522280     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089707     Document Type: Article

References (26)

1. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995;333:166-174.
2. Sherrard DJ, Hercz G, Pei Y, et al: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993;43:436-442.
3. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-236.
4. Slatopolsky E, Finch J, Denda M, Ritter C, et al: Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-2540.
5. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984;74:2136-2143.
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
7. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
8. Stehman-Breen CO, Sherrard DJ, Alem AM et al: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58:2200-2205.
9. K/DOQI Clinical practice guidelines for bone metabolism and disease in CKD. VI. Serum calcium and calcium-phosphorus product. October 2003.
10. Sprague SM, Moe SM: Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 1992;19:532-539.
11. Slatopolsky E, Finch J, Brown A: New vitamin D analogs. Kidney Int 2003;85:S83-S87.
12. Upton RA, Knutson JC, Bishop CW, LeVan LW: Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. Nephrol Dial Transplant 2003;18:750-758.
13. Delmez JA, Tindira C, Grooms P, et al: Parathyroid hormone suppression by 1,25-dihydroxyvitamin D, a role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-1355.
14. 2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532-543.
15. 2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis. J Am Soc Nephrol 1998;10:1427-1432.
16. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995;26:852-860.
17. 3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002;40:1283-1288.
18. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
19. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;28:S51-S56.
20. Coburn JW, Maung HM, Elangovan L, et al: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-890.
21. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
22. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM: Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004;19:1174-1181.
23. 2, a new analog of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 1998;32:S40-S47.
24. 2 on calcium resolution in bone. J Am Soc Nephrol 1999;10:980-985.
25. 3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;1139:279-284.
26. Balint E, Marshall CF, Sprague SM: Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 2000;36:789-796.